(Q37850819)

24 August 2017

1 reference

title

Zoledronic acid for prevention and treatment of osteoporosis (English)

1 reference

24 August 2017

0 references

1 reference

Chris Recknor

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

9 March 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

807-815

1 reference

Osteoporosis: a still increasing prevalence

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Loss of treatment benefit due to low compliance with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Low-energy femoral shaft fractures associated with alendronate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Severely suppressed bone turnover and atypical skeletal fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Adverse effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Hip fracture incidence among the old and very old: a population-based study of 745,435 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.562201

10.1517/14656566.2011.562201

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference